Russia's R-Pharm eyes expansion in domestic market

7 March 2023

The Russian drugmaker R-Pharm is accelerating its expansion in the domestic market this year with the planned investments of 4 billion roubles ($100 million) in the building a new production facility in St Petersburg and the establishment of a large-scale production in the capital city of Moscow.

In the case of Moscow, the company became the winner of the tender announced by the Moscow government, reports The Pharma Letter’s local correspondent.

Under the terms of the tender, the company will launch the production of two anti-cancer drugs - daratumumab (Johnson & Johnson’s [NYSE: JNJ] Darzalex) and pembrolizumab (Merck & Co’s [NYSE: MRK] Keytruda), as well as ustekinumab (J&J’s Stelara), an immunosuppressants for the treatment of psoriasis and tocilizumab (Roche’s [ROG: SIX] Actemra/RoActemra), for rheumatoid arthritis and systemic juvenile idiopathic arthritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK